Skip to main content
Book cover

Clinically Relevant Resistance in Cancer Chemotherapy

  • Book
  • © 2002

Overview

Part of the book series: Cancer Treatment and Research (CTAR, volume 112)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (17 chapters)

Keywords

About this book

Over the last several decades, the introduction of new chemotherapeutic drugs and drug combinations has resulted in increased long­ term remission rates in several important tumor types. These include childhood leukemia, adult leukemias and lymphomas, as well as testicular and trophoblastic tumors. The addition of high-dose chemotherapy with growth factor and hemopoietic stem cell support has increased clinical remission rates even further. For the majority of patients with some of the more common malignancies, however, palliation (rather than cure) is still the most realistic goal of chemotherapy for metastatic disease. The failure of chemotherapy to cure metastatic cancer is commonly referred to among clinicians as "drug resistance". This phenomenon can, however, often be viewed as the survival of malignant cells that resulted from a failure to deliver an effective drug dose to the (cellular) target because of anyone of or combination of a multitude of individual factors. Clinically, this treatment failure is often viewed as the rapid occurrence of resistance at the single cell level. However, in experimental systems, stable drug resistance is usually relatively slow to emerge.

Editors and Affiliations

  • MD Anderson Cancer Center, Houston, USA

    Borje Andersson

  • Cross Cancer Institute, Edmonton, Canada

    David Murray

Bibliographic Information

  • Book Title: Clinically Relevant Resistance in Cancer Chemotherapy

  • Editors: Borje Andersson, David Murray

  • Series Title: Cancer Treatment and Research

  • DOI: https://doi.org/10.1007/978-1-4615-1173-1

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Springer Science+Business Media New York 2002

  • Hardcover ISBN: 978-1-4020-7200-0Published: 31 October 2002

  • Softcover ISBN: 978-1-4613-5428-4Published: 23 October 2012

  • eBook ISBN: 978-1-4615-1173-1Published: 06 December 2012

  • Series ISSN: 0927-3042

  • Series E-ISSN: 2509-8497

  • Edition Number: 1

  • Number of Pages: XX, 380

  • Topics: Oncology, Cancer Research

Publish with us